The first-in-man use of the Coherex WaveCrest left atrial appendage (LAA) occluder system was successfully performed recently in New Zealand, launching the WAVECREST 1 trial to evaluate the device's effectiveness. The trial is being carried out in New Zealand, Australia and several European countries and will be used to seek CE mark approval for the device.
